DCTHDelcath Systems, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~11% a year FCF growth. The price demands less than its three-year revenue growth of 231% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What DCTH's price assumes
Delcath Systems, Inc. has no trailing P/E on file, so the price is measured against sales instead: 3.54× revenue.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 3.4%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- +11%
Growth the price implies · The price pays for +11% free cash flow growth a year for a decade; revenue has grown +231% a year over the last three.
- Price / book
- 2.84
Price / book · as of 2026-Q1
Details›
- Price / bookas of 2026-Q1
- 2.84
- EV / EBIToperating margin −1.9%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q1
- 3.10
- Free cash flow, trailing twelve months
- $18M
- Market capitalisation
- $519M
- 3-year revenue growth
- +231%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.